Aristotle University Of Thessaloniki (AUTH)
Η εφαρμογή του ραδιοεπισημασμένου αναλόγου της σωματοστατίνης ⁹⁹ᵐTc-depreotide στην διαγνωστική προσέγγιση του μεταστατικού καρκίνου του θυρεοειδούς
Abstract
dc:descriptionDuring the last twenty years, the discovery of human somatostatin receptors in cancer cells of neuroendocrine or other origin, including thyroid carcinoma, led to the application of the synthetic analogue of the endogenous hormone somatostatin, indium-111-labeled DTPA-octreotide (¹¹¹In-pentetreotide), for the detection of iodine-negative metastases of differentiated thyroid cancer, as well as medullary thyroid cancer metastatic lesions. The aim of the present study was the evaluation of the newer synthetic somatostatin analogue, depreotide, which is labeled with technetium-99m (⁹⁹ᵐTc-depreotide), in restaging thyroid cancer. Whole-body and tomographic (single-photon emission tomography- SPET) scintigraphy was performed in post-surgical thyroid cancer patients with increased specific tumor markers or ambiguous radiological findings. Concerning the whole group of our patients, the ⁹⁹ᵐTc-depreotide findings were coevaluated with those of the conventional radiological methods and presented a sensitivity of 86,9% and 70,8%, and a specificity of 66,6% and 87,5%, respectively. Also, our results were correlated with the established radionuclide techniques. In some cases, the combination of clinical, laboratory and imaging methods, or histopathology after surgical dissection of metastatic invasion provided the definitive diagnosis, while in others confirmation was accomplished by the course of the disease during two-year follow-up. Scintigraphy with ⁹⁹ᵐTc-depreotide demonstrates high sensitivity in the detection of thyroid cancer metastatic lesions, directly reflecting the disease development at the pathophysiological level. In patients with differentiated thyroid cancer, it appears to portray the non-iodophilic metastatic foci, without the need for thyroxine withdrawal or recombinant human thyrotropin application. Our preliminary results in patients with recurrent and/or metastatic differentiated or medullary thyroid cancer, indicate a positive correlation between the tracer uptake and serum thyroglobulin or calcitonin levels, respectively. Further studies in larger patient population may establish a definite correlation as well as its clinical impact. Moreover, the method involves relatively low radioactive burden to the patients. Finally, it allows the application of alternative therapeutic approaches, with the utilization of "cold" or "hot" somatostatin analogues, which have lately acquired access in clinical practice. Scintigraphy with ⁹⁹ᵐTc-depreotide should be considered as a useful adjunct to the armamentarium for thyroid cancer follow-up, since it provides valuable information, especially in the setting of increased serum thyroglobulin and/or calcitonin levels and negative whole-body scan with ¹³¹I or ¹²³/¹³¹I-MIBG I-MIBG or ⁹⁹ᵐT -(V)DMSA.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2008
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Valsamaki, Pipitsa
- Βαλσαμάκη, Πιπίτσα
Subjects
dc:subject × 13Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/22545